Skip to content
  • Sunday, 26 July 2026
  • 2:51 am
  • Follow Us
Lab DB
  • Home
  • About Us
    • About Us
    • Affiliate Disclosure
    • Cookie Policy
    • Disclaimer
    • Privacy Policy
    • DMCA
    • Terms of Service
  • Contact Us
  • FAQ
  • Home
  • Eli Lilly’s Retatrutide Achieves Unprecedented Weight Loss in TRIUMPH-1 Trial, Signaling New Era in Obesity Pharmacotherapy
Pharmaceutical R&D

Eli Lilly’s Retatrutide Achieves Unprecedented Weight Loss in TRIUMPH-1 Trial, Signaling New Era in Obesity Pharmacotherapy

Teuku Ryan Jun 18, 2026 0

NEW ORLEANS, LOUISIANA – At the 86th Scientific Sessions of the American Diabetes Association (ADA) held in New Orleans, Louisiana,…

Read More
Pharmaceutical R&D

Revolution Medicines’ Daraxonrasib Achieves Landmark Survival Extension in Pancreatic Cancer, Heralding New Era of Targeted Therapy

Teuku Ryan Jun 2, 2026 0

The field is ecstatic about the prospect of a targeted therapy meaningfully extending overall survival in pancreatic cancer. The 2026…

Read More
Advanced Materials Science

Quantum Metasurface Integration Breakthrough Achieves Twenty-Fold Efficiency Gain in Terahertz Radiation Detection

Nila Kartika Wati Jun 1, 2026 0

The detection of electromagnetic radiation across various spectra serves as the backbone of modern technological infrastructure, facilitating everything from fiber-optic…

Read More
Advanced Materials Science

International Research Team Achieves Breakthrough in Long Distance Quantum Key Distribution Using Semiconductor Quantum Dots and Time Bin Encoding

Nila Kartika Wati May 25, 2026 0

The landscape of global cybersecurity is on the precipice of a paradigm shift as researchers move closer to realizing a…

Read More
Laboratory Automation & Robotics

Lilly’s triple agonist achieves 16.8% weight loss in phase 3 trial

Lana Keisha May 4, 2026 0

Eli Lilly and Company today announced groundbreaking results from a Phase 3 clinical trial for its investigational triple agonist, retatrutide,…

Read More
Laboratory Automation & Robotics

Eli Lilly’s Triple Agonist Achieves 16.8% Weight Loss in Phase 3 Trial

Lana Keisha Apr 27, 2026 0

Eli Lilly and Company today announced groundbreaking results from a Phase 3 clinical trial for its investigational triple agonist, retatrutide,…

Read More
Laboratory Automation & Robotics

Lilly’s triple agonist achieves 16.8% weight loss in phase 3 trial.

Lana Keisha Apr 19, 2026 0

Eli Lilly and Company today announced groundbreaking results from a Phase 3 clinical trial for its investigational triple agonist, retatrutide,…

Read More
Advanced Materials Science

Breakthrough in MXene Synthesis Achieves Unprecedented Electrical Conductivity and Surface Precision Through Novel Molten Salt Technique

Nila Kartika Wati Apr 19, 2026 0

A collaborative research effort led by the Institute of Ion Beam Physics and Materials Research at the Helmholtz-Zentrum Dresden-Rossendorf (HZDR)…

Read More
Laboratory Automation & Robotics

Lilly’s triple agonist achieves 16.8% weight loss in phase 3 trial

Lana Keisha Apr 12, 2026 0

Eli Lilly’s investigational drug, retatrutide, a pioneering first-in-class GIP, GLP-1, and glucagon triple hormone receptor agonist, has delivered extraordinary results…

Read More
Advanced Materials Science

Breakthrough in MXene Synthesis Achieves Unprecedented Electrical Conductivity and Surface Precision Through Novel Molten Salt Technique

Nila Kartika Wati Apr 12, 2026 0

A collaborative research effort led by the Institute of Ion Beam Physics and Materials Research at the Helmholtz-Zentrum Dresden-Rossendorf (HZDR)…

Read More

Posts pagination

1 2
Decentralizing Development: The Rise of Free, Offline AI Coding Assistants with OpenCode, Ollama, and Qwen3-CoderQuantum Entanglement Observed in Macroscopic Strange Metal Crystals Redefines Material Science BoundariesResearchers Discover Method to Manipulate Turbulent Energy Flux Challenging Decades of Established Physics TheoryThe Aging Atlas: Unlocking the Secrets of Cellular Decline Across Mammalian Tissues
MEDVi Under Scrutiny: AI-Powered Telehealth Startup Faces FDA Warnings, Deceptive Marketing Allegations, and Multiple Lawsuits Despite Meteoric GrowthLLMOps in 2026: The 10 Tools Every Team Must HaveJapan’s FY26 NHI Drug Price Revision: Deeper Dive into Mechanisms and Market ImpactThe Most Favored Nation (MFN) Policy’s Unforeseen Ripple Effect: European Pharmaceutical Launches and Withdrawals Plummet
Remepy, a startup that pairs drugs with AI-driven apps, clears a Phase IIa test in Parkinson’sKing’s College London Researchers Identify Potential Breakthrough Alzheimer’s Treatment Through Repurposed Spinal Cord Injury Drug KCL-286Living Plastics That Self-Destruct: Scientists Engineer Microbe-Embedded Polymers for Complete and Rapid DecompositionSanofi Discontinues Amlitelimab Development in Atopic Dermatitis, Citing Lack of Meaningful Differentiation
YOU MAY HAVE MISSED
Laboratory Automation & Robotics
Remepy, a startup that pairs drugs with AI-driven apps, clears a Phase IIa test in Parkinson’s
Lana Keisha Jul 25, 2026
Neuroscience & Brain Research
King’s College London Researchers Identify Potential Breakthrough Alzheimer’s Treatment Through Repurposed Spinal Cord Injury Drug KCL-286
Rifan Muazin Jul 25, 2026
Advanced Materials Science
Living Plastics That Self-Destruct: Scientists Engineer Microbe-Embedded Polymers for Complete and Rapid Decomposition
Nila Kartika Wati Jul 25, 2026
Pharmaceutical R&D
Sanofi Discontinues Amlitelimab Development in Atopic Dermatitis, Citing Lack of Meaningful Differentiation
Teuku Ryan Jul 25, 2026

Copyright © 2025 | Powered by WordPress | News Gadgets by ThemeArile

  • Home
  • About Us
    • About Us
    • Affiliate Disclosure
    • Cookie Policy
    • Disclaimer
    • Privacy Policy
    • DMCA
    • Terms of Service
  • Contact Us
  • FAQ